Adverse Prognostic Impact of Bone Marrow Microvessel Density in Multiple Myeloma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Angiogenesis is important for the proliferation and survival of multiple myeloma (MM) cells. Bone marrow (BM) microvessel density (MVD) is a useful marker of angiogenesis and is determined by immunohistochemical staining with anti-CD34 antibody. This study investigated the prognostic impact of MVD and demonstrated the relationship between MVD and previously mentioned prognostic factors in patients with MM. Methods: The study included 107 patients with MM. MVD was assessed at initial diagnosis in a blinded manner by two hematopathologists who examined three CD34-positive hot spots per patient and counted the number of vessels in BM samples. Patients were divided into three groups according to MVD tertiles. Cumulative progression-free survival (PFS) and overall survival (OS) curves, calculated by using Kaplan-Meier method, were compared among the three groups. Prognostic impact of MVD was assessed by calculating Cox proportional hazard ratio (HR). Results: Median MVDs in the three groups were 16.8, 33.9, and 54.7. MVDs were correlated with other prognostic factors, including β2-microglobulin concentration, plasma cell percentage in the BM, and cancer stage according to the International Staging System. Multivariate Cox regression analysis showed that high MVD was an independent predictor of PFS (HR=2.57; 95% confidence interval, 1.22-5.42; P=0.013). PFS was significantly lower in the high MVD group than in the low MVD group (P=0.025). However, no difference was observed in the OS (P=0.428). Conclusions: Increased BM MVD is a marker of poor prognosis in patients newly diagnosed with MM. BM MVD should be assessed at the initial diagnosis of MM.
Abstract
Background: Angiogenesis is important for the proliferation and survival of multiple myeloma (MM) cells. Bone marrow (BM) microvessel density (MVD) is a useful marker of angiogenesis and is determined by immunohistochemical staining with anti-CD34 antibody. This study investigated the prognostic impact of MVD and demonstrated the relationship between MVD and previously mentioned prognostic factors in patients with MM. Methods: The study included 107 patients with MM. MVD was assessed at initial diagnosis in a blinded manner by two hematopathologists who examined three CD34-positive hot spots per patient and counted the number of vessels in BM samples. Patients were divided into three groups according to MVD tertiles. Cumulative progression-free survival (PFS) and overall survival (OS) curves, calculated by using Kaplan-Meier method, were compared among the three groups. Prognostic impact of MVD was assessed by calculating Cox proportional hazard ratio (HR). Results: Median MVDs in the three groups were 16.8, 33.9, and 54.7. MVDs were correlated with other prognostic factors, including β2-microglobulin concentration, plasma cell percentage in the BM, and cancer stage according to the International Staging System. Multivariate Cox regression analysis showed that high MVD was an independent predictor of PFS (HR=2.57; 95% confidence interval, 1.22-5.42; P=0.013). PFS was significantly lower in the high MVD group than in the low MVD group (P=0.025). However, no difference was observed in the OS (P=0.428). Conclusions: Increased BM MVD is a marker of poor prognosis in patients newly diagnosed with MM. BM MVD should be assessed at the initial diagnosis of MM.
참고문헌 (24)
- Bergers G, "Tumorigenesis and the angiogenic switch", Nat Rev Cancer, 3, pp.401~410 (2003)
- Hong L, "The role of epidermal growth factor receptor in prognosis and treatment of gastric cancer", Expert Rev Gastroenterol Hepatol, 8, pp.111~117 (2014)
- Jakob C, "Angiogenesis in multiple myeloma", Eur J Cancer, 42, pp.1581~1590 (2006)
- Fan F, "Targeting the tumor microenvironment: focus on angiogenesis", J Oncol, 2012, pp.281261~ (2012)
- Liu Y, "Microvesicles secreted from human multiple myeloma cells promote angiogenesis", Acta Pharmacol Sin, 35, pp.230~238 (2014)
- Vacca A, "Bone marrow angiogenesis in multiple myeloma", Leukemia, 20, pp.193~199 (2006)
- Niemöller K, "Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III", J Cancer Res Clin Oncol, 129, pp.234~238 (2003)
- Oh HS, "Comparison of microvessel density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications: multicenter trial", Int J Hematol, 76, pp.465~470 (2002)
- Pruneri G, "Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients", Br J Haematol, 118, pp.817~820 (2002)
- Sezer O, "Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma", Ann Hematol, 79, pp.574~577 (2000)
- Rajkumar SV, "Prognostic value of bone marrow angiogenesis in multiple myeloma", Clin Cancer Res, 6, pp.3111~3116 (2000)
- Kyle RA, "Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma", Leukemia, 23, pp.3~9 (2009)
- Anderson KC, "Clinically relevant end points and new drug approvals for myeloma", Leukemia, 22, pp.231~239 (2008)
- Bhatti SS, "Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters", Am J Hematol, 81, pp.649~656 (2006)
- Cohen J., "Statistical power analysis for the behavioral sciences" (1988), Lawrence Erlbaum Associates
- Fonseca R, "International Myeloma Working Group molecular classification of multiple myeloma: spotlight review", Leukemia, 23, pp.2210~2221 (2009)
- Kumar S, "Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy", Bone Marrow Transplant, 34, pp.235~239 (2004)
- Ahn MJ, "Clinical significance of microvessel density in multiple myeloma patients", J Korean Med Sci, 16, pp.45~50 (2001)
- Choi JH, "Absence of clinical prognostic value of vascular endothelial growth factor and microvessel density in multiple myeloma", Int J Hematol, 76, pp.460~464 (2002)
- Giuliani N, "Angiogenesis and multiple myeloma", Cancer Microenviron, 4, pp.325~337 (2011)
- Munshi NC, "Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2", Blood, 117, pp.4696~4700 (2011)
- Rana C, "Bone marrow angiogenesis in multiple myeloma and its correlation with clinicopathological factors", Ann Hematol, 89, pp.789~794 (2010)
- Sprindzuk M, "Computer-aided Image Processing of Angiogenic Histological", J Clin Med Res, 1, pp.249~261 (2009)
- Babarović E, "Assessment of bone marrow fibrosis and angiogenesis in monitoring patients with multiple myeloma", Am J Clin Pathol, 137, pp.870~878 (2012)